Roche says fake MabThera has surfaced in EU

Roche ($RHHBY) is again tracking down counterfeits of some of its cancer meds in Europe after an importer in Germany discovered the fakes. In this case, it is counterfeit MabThera, sold as Rituxan in the U.S. In the spring, authorities in Europe launched an investigation into fake or compromised vials of Herceptin that were stolen from Italian hospitals, tampered with and then reintroduced into the EU supply chain. The Swiss company said in an email that it delivered the product to a wholesaler in Romania and had no control of it after that. It is no big surprise that counterfeiters are targeting MabThera. It is Roche's best-selling drug and the best-selling cancer drug in the world, with 2013 revenues of $7.78 billion. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.